Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

Craig LaForce,1 Gregory Feldman,2 Selwyn Spangenthal,3 Joerg H Eckert,4 Michelle Henley,5 Francesco Patalano,4 Peter D’Andrea5 1North Carolina Clinical Research, Raleigh, NC, USA; 2South Carolina Pharmaceutical Research, Spartanburg, SC, USA; 3American Health Research, Charlotte, NC, USA;...

Full description

Bibliographic Details
Main Authors: LaForce C, Feldman G, Spangenthal S, Eckert JH, Henley M, Patalano F, D’Andrea P
Format: Article
Language:English
Published: Dove Medical Press 2016-06-01
Series:International Journal of COPD
Subjects:
glycopyrronium
glycopyrrolate
lung function
chronic obstructive pulmonary disease
long-acting muscarinic agonist
bronchodilator
twice daily
Online Access:https://www.dovepress.com/efficacy-and-safety-of-twice-daily-glycopyrrolate-in-patients-with-sta-peer-reviewed-article-COPD

Internet

https://www.dovepress.com/efficacy-and-safety-of-twice-daily-glycopyrrolate-in-patients-with-sta-peer-reviewed-article-COPD

Similar Items